Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can one small incision replace multiple for lung cancer surgery?

NCT ID NCT07790406

Disease control Sponsor: European Institute of Oncology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

Researchers are studying whether a single-port robotic system can remove early-stage lung cancer through one small incision instead of several openings between the ribs. The approach aims to reduce pain and speed up recovery while keeping the same safety and cancer-fighting results as standard surgery. The study includes 50 people with stage I non-small cell lung cancer who have or will have a lobectomy with lymph node removal. The team will collect and review data from these procedures to describe their experience with this technique.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
da Vinci Single-Port surgical system for lobectomy
What this could lead to
If it works, this approach could offer a less painful, faster-recovering option for early-stage lung cancer surgery without compromising cancer control.
What could go wrong
This is a small, single-center study collecting experiences, not a large controlled trial. Results may not apply broadly, and robotic surgery still carries standard surgical risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Dec 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include all patients with proven non-small cell lung cancer (NSCLC) clinical stage I (9th TNM edition), who have undergone or will undergo lobectomy plus radical lymph node dissection following the STS guide line

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * all patients with proven non-small cell lung cancer (NSCLC) clinical stage I (9th TNM edition), who have undergone or will undergo lobectomy plus radical lymph node dissection following the STS guide line Exclusion Criteria: * no consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer (NSCLC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istituto Europeo di Oncologia

    RECRUITING

    Milan, Mi, 20141, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.